Clinical Protocol and Data management (CPDM) at Fox Chase Cancer Center (FCCC) is spearheaded by the Clinical Trials Office (CTO). The CTO provides central management, research support and oversight functions for the conduct of cancer-related clinical trials for the Cancer Center. CTO services are provided for all interventional treatment trials conducted within the Cancer Center, including those at FCCC?s Main Campus, FCCC?s Bone Marrow Transplant Unit and the Temple University Health Science Center. For other cancer relevant clinical research, the CTO facilitates study submission, ongoing management of study materials and annual reviews; however, most researchers utilize research staff within their department to perform the conduct of the study. The CTO has particular responsibility for institutional treatment trials developed by Cancer Center members. Along with the Quality Assurance (QA) group of the CTO, research teams are trained to support the conduct of each trial. Studies are audited internally by the QA group to ensure eligibility and compliance to protocols, as well as appropriate reporting of serious adverse events. They participate in developing corrective action plans for issues identified by internal or external auditors. They also facilitate the review of Early Phase Clinical Trials and Investigator-initiated Trials by the FCCC Data Safety Monitoring Committee. From 2011 to 2014, accrual to Interventional Treatment Trials rose from 358 to 668 (an 87% increase), and to Interventional Investigator-initiated Treatment Trials from 77 to 287 (273% increase).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006927-54S4
Application #
10113014
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
54
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Auerbach, M V; Heckman, C J; Darlow, S (2018) To protect or not to protect: examining reasons for sun protection among young women at risk for skin cancer. J Behav Med 41:528-536
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Mazor, Anna M; Mateo, Alina M; Demora, Lyudmila et al. (2018) Breast conservation versus mastectomy in patients with T3 breast cancers (>?5 cm): an analysis of 37,268 patients from the National Cancer Database. Breast Cancer Res Treat :
Ingram, Justin P; Tursi, Sarah; Zhang, Ting et al. (2018) A Nonpyroptotic IFN-?-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol 200:3626-3634
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298

Showing the most recent 10 out of 1280 publications